NasdaqGS:VIRBiotechs
Is Vir Biotechnology (VIR) Quietly Recasting Its Governance Strength With a New Audit Committee Chair?
In June 2026, Vir Biotechnology’s Board expanded from seven to eight members and appointed Timothy Coughlin, CPA, as a Class III director and Chair of the Audit Committee, effective June 9, 2026.
Coughlin’s audit leadership experience and history guiding biotech companies through regulatory and commercial inflection points could influence how investors view Vir’s governance and execution capabilities.
We’ll now examine how adding an experienced audit committee chair like Coughlin may shape...

